Market Overview

UPDATE: Jefferies Raises PT on Abbott Laboratories on Attractive Valuation

Share:
Related ABT
The Biggest Mergers Currently Stuck In Regulatory Purgatory
All The Markets Trump Moved During His Speech Today
Low-Yield Dividend Stocks Belong in Your Portfolio (GuruFocus)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), and raised the price target from $40.00 to $42.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Abbott Laboratories closed on Tuesday at $36.55.

Latest Ratings for ABT

DateFirmActionFromTo
Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy
Jul 2016JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!